Letter

Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism

BMJ 1995; 311 doi: 10.1136/bmj.311.6997.124b (Published 8 July 1995)
Cite this as: BMJ 1995;311:124.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. A Fournier,
  2. R Oprisiu,
  3. N E L Esper,
  4. P Moriniere,
  5. A Marie
  1. Professor Attached doctor Hospital practitioners Centre Hospitalier Universitaire d'Amiens, Salouel, 80054 Amiens Cedex 1, France

    EDITOR,--Neveen A T Hamdy and colleagues report a placebo controlled trial of alfacalcidol in patients with mild to moderate renal failure.1 They conclude that alfacalcidol might be used more widely in these patients. Before we accept their conclusion we would appreciate answers to the following points.

    Firstly, since the conclusions are based on histomorphometric data on bone we would like to know the normal ranges for these histomorphometric variables, the criteria used to show that the number of osteoclasts and osteoblasts was increased, and the significance of the difference in the number of bone cells between the two groups at the end of the trial. …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular